PCSK9 and endothelial dysfunction: In-vivo deletion of PCSK9 in PCSK9-/- mice also significantly reduced SA-β-gal activity in aged ECs and the aortic arch, whereas treatment of aged mice with recombinant PCSK9 accentuated SA-β-gal activity in this vessel that is prone to disturbed flow accompanied by endothelial dysfunction.